http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019520308-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6879 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-537 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2017-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019520308-A |
| titleOfInvention | Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| abstract | The present invention is directed to novel B7-H3 binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that cross-react with non-human primate (eg cynomolgus monkey) B7-H3. The invention further provides a B7- comprising a variable light chain and / or variable heavy chain (VH) domain humanized and / or de-immunized to exhibit reduced immunogenicity upon administration to a recipient subject. It relates to H3 binding molecules. The invention particularly relates to: a bispecific diabody, BiTE, bispecific comprising (i) the above B7-H3 binding variable domain; and (ii) a domain capable of binding to an epitope of a molecule present on the surface of effector cells. The invention relates to bispecific, trispecific or multispecific B7-H3 binding molecules, including sexual antibodies, trivalent binding molecules and the like. The present invention is also directed to pharmaceutical compositions containing any of the above B7-H3 binding molecules and methods involving the use of any of the above B7-H3 binding molecules in the treatment of cancer and other diseases and conditions. The invention also relates to a molecule comprising a human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety ("B7-H3-ADC"). The present invention is also directed to pharmaceutical compositions containing the B7-H3-ADC as described above, and methods involving the use of any of the B7-H3-ADCs as described above in the treatment of cancer and other diseases and conditions. |
| priorityDate | 2016-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 564.